CMND

Clearmind Medicine Inc. (CMND) SWOT Analysis Analysis (2026)

Invetso Score: 3.8/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 4.2 (Moderate)

Extremely negative cash conversion cycle suggests very fast working-capital turnover versus peers, supporting liquidity efficiency despite limited profitability visibility.

Current and quick ratios near 4.8x indicate a substantially stronger short-term liquidity buffer than most peers, reducing near-term funding pressure.

Debt-to-equity is only 0.007x, implying materially lower balance-sheet leverage than peers and preserving financial flexibility.

Net debt to EBITDA of 1.54x remains manageable relative to many leveraged peers, limiting refinancing risk and supporting resilience.

Weaknesses

Score:

Return on invested capital is -69.9%, showing capital is not generating economic returns and lagging profitable peers by a wide margin.

The absence of reported operating and gross margins limits evidence of durable unit economics, leaving the business structurally weaker than transparent peers.

Negative ROIC alongside leverage above zero indicates capital structure is not yet translating into value creation, unlike stronger peer operators.

The very large negative cash conversion cycle may reflect working-capital distortions rather than true operating strength, making peer comparison less reliable.

Opportunities

Score:

If working-capital efficiency is sustainable, CMND can convert liquidity strength into faster reinvestment than peers, improving competitive flexibility over time.

Low leverage leaves room to fund growth or restructuring more easily than indebted peers, which can support strategic optionality.

A strong current ratio provides a cushion to absorb volatility and pursue operational improvements without immediate external financing pressure.

Any normalization of profitability from negative ROIC toward peer levels would create outsized upside because the starting base is deeply depressed.

Threats

Score:

Persistent negative ROIC threatens long-term value destruction and leaves CMND structurally behind peers that compound capital at positive returns.

If the negative cash conversion cycle reverses, liquidity could tighten quickly because the current advantage may be driven by timing effects rather than durable economics.

Limited margin disclosure increases execution uncertainty versus peers, making it harder to prove sustainable operating improvement to investors and counterparties.

Higher leverage than cash-rich peers still leaves CMND exposed if earnings weaken, because modest debt can matter when profitability is already negative.

Overall Score

Score:

CMND shows strong liquidity and low leverage, but deeply negative ROIC and limited profitability evidence leave its structural positioning below stronger peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Clearmind Medicine Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →